Article thumbnail
Location of Repository

The clinical application of PET/CT: a contemporary review

By Z. Brady, M. L. Taylor, M. Haynes, M. Whittaker, A. Mullen, L. Clews, M. Partridge, R. J. Hicks and Jamie V. Trapp

Abstract

The combination of positron emission tomography (PET) scanners and x-ray computed tomography (CT) scanners into a single PET/CT scanner has resulted in vast improvements in the diagnosis of disease, particularly in the field of oncology. A decade on from the publication of the details of the first PET/CT scanner, we review the technology and applications of the modality. We examine the design aspects of combining two different imaging types into a single scanner, and the artefacts produced such as attenuation correction, motion and CT truncation artefacts. The article also provides a discussion and literature review of the applications of PET/CT to date, covering detection of tumours, radiotherapy treatment planning, patient management, and applications external to the field of oncology

Topics: 029903 Medical Physics, 110320 Radiology and Organ Imaging, 111299 Oncology and Carcinogenesis not elsewhere classified, 111208 Radiation Therapy, PET/CT, PET, CT, applications, oncology, treatment planning, nuclear medicine
Publisher: Australasian College of Physical Scientists and Engineers in Medicine
Year: 2008
OAI identifier: oai:eprints.qut.edu.au:15343

Suggested articles

Citations

  1. (2006). [18F] fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer,
  2. A knowledge-based method for reducing attenuation artefacts caused by cardiac appliances in myocardial PET/CT,
  3. (2007). A microPET/CT system for in vivo small animal imaging,
  4. (2007). A scatter-corrected list-mode reconstruction and a practical scatter / random approximation technique for dynamic PET imaging,
  5. (2004). Acquisition protocol considerations for combined PET/CT imaging,
  6. Application of Intravenous Contrast in PET/CT: Does It Really Introduce Significant Attenuation Correction Error?,
  7. Benefit of Time-of-Flight in PET: Experimental and Clinical Results,
  8. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study,
  9. (2007). Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma,
  10. (2002). Clinical PET/CT scanning using oral CT contrast agents,
  11. (2002). Combined Functional and Structural Evaluation of Cancer Patients with a Hybrid Camera-Based PET/CT System Using 18F-FDG,
  12. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer,
  13. (2005). Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer,
  14. (2005). Comparison of CT- and FDG-PET-Defined Gross Tumor Volume in Intensity-Modulated Radiotherapy for Head-and-Neck Cancer,
  15. (2004). Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors,
  16. (2004). Computed Tomography: Fundamentals, System Technology,
  17. (1973). Computerized transverse axial scanning (tomography): Part 1. Description of system,
  18. (1973). Computerized transverse axial tomography,
  19. (2003). Correction for Oral Contrast Artifcats in CT Attenuation-Corrected PET Imagins Obtained by Combined PET/CT,
  20. (2008). CT attenuation correction for Australas.
  21. Detection of metallic implantassociated infections with FDG PET in patients with trauma: correlation with microbiologic results,
  22. Detection of musculoskeletal infection with 18F-FDG PET: Review of the current literature,
  23. (2004). Detection of Recurrence in Patients with Rectal Cancer:
  24. (2006). Development of a GSO positron / single-photon imaging detector,
  25. (1999). Dose reduction in CT by anatomically adapted tube current modulation.
  26. (1999). Dose reduction in CT by anatomically adapted tube current modulation. I. Simulation studies,
  27. (2008). Dual-Modality PET/CT Scanning with Negative Oral Contrast Agent to Avoid Artifacts: Introduction and Evaulation, Radiology,
  28. Elevated F-18 FDG uptake in plasmacyte-rich chronic maxillary sinusitis,
  29. (2004). Emission Tomography: The Fundamentals of PET and SPECT: The Fundamentals of Pet and Spect,
  30. (2000). F-18-FDG uptake in breast infection and inflammation,
  31. F-18-FDG uptake in tuberculosis,
  32. FDG PET imaging in musculoskeletal infection,
  33. (2001). FDG PET Imaging in Patients with Lymphoma: A Clinical Perspective,
  34. FDG-PET CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma,
  35. (2005). FDG-PET evaluation of vaginal carcinoma,
  36. FDG-PET/CT in re-staging of patients with lymphoma,
  37. FDGPET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy,
  38. (1994). Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography,
  39. (1998). Fluorine-18-fluorodeoxyglucose uptake in pneumonia,
  40. (2005). Fluorocholine PET/CT in patients with prostate cancer: initial experience,
  41. (2003). Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis,
  42. (2007). Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer,
  43. (2004). Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion,
  44. (2002). Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants,
  45. (1989). High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study,
  46. High Accuracy Multiple Scatter Modelling for 3D Whole Body PET,
  47. (2004). Hybrid PET-CT Simulation for Radiation Treatment Planning in Head and Neck Cancers: A Brief Technical Report,
  48. (2000). Image analysis in oncology patients studied with a combined PET/CT scanner,
  49. (2006). Imaging Prostate Cancer with 11C-Choline PET/CT,
  50. (2004). Impact of FDG-PET on Radiation Therapy Volume Delineation in Non-Small-Cell Lung Cancer,
  51. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma,
  52. (2007). Impact of Hybrid Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography on Radiotherapy Planning in Esophageal and Non-Small Cell Lung Cancer,
  53. (2006). Improvements in Cancer Staging with PET/CT: Literaturebased evidence as of Septebmer
  54. (2006). Initial experience with FDG PET/CT in the evaluation of breast cancer,
  55. (2006). Integrated PET/CT: Current applications and future directions,
  56. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CTimages of head and neck cancers,
  57. (2007). Investigation of a whole-body DOIPET system,
  58. (2004). Is 18F-FDG PET/CT Useful for Imaging and Management of Patients with Suspected Occult Recurrence of Cancer,
  59. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?,
  60. Lutetium oxyorthosilicate block detector readout by avalanche photodiode arrays for high resolution animal PET,
  61. (2004). Malignant Involvement in the Spine: Assessment by 18F-FDG PET/CT,
  62. (2007). Mediastinal Nodal Staging of Nonsmall Cell Lung Cancer Using Integrated 18F-FDG PET/CT in a Tuberculosis-Endemic Country: Diagnostic Efficacy in 674 Patients,
  63. (1999). Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of
  64. (2003). MicroPET II: design, development and initial performance of an improved microPET scanner for small animal-imaging,
  65. (1996). Model-based scatter correction for fully 3D PET,
  66. (2008). Multimodality imaging of structure and function,
  67. (2005). Myocardial blood flow measurement by PET: Technical aspects and clinical applications,
  68. (2006). Noninvasive Characterization of Myocardial Molecular Interventions by Integrated Positron Emission Tomography and Computed Tomography,
  69. (2004). Optimisation of a fully 3D single scatter simulation algorithm for 3D PET,
  70. Optimization and performance evaluation of the microPETII scanner for in vivo small-animal imaging,
  71. (2007). Performance of a Philips Gemini TF PET/CT Scanner with Special Consideration for Its Time-of-Flight Imaging Capabilities,
  72. (2006). Performance test of an LSO-APD Detector in a 7-T MRI Scanner for Simultaneous PET/MRI,
  73. (2005). PET / CT: Challenge for nuclear cardiology,
  74. PET and PET/CT in fever of unknown origin,
  75. PET Definition of Gross Tumor Volume for Radiotherapy of Non– Small Cell Lung Cancer: Is a Single Standardized Uptake Value Threshold Approach Appropriate?,
  76. PET in candidates for radiation therapy: is it important and how do we validate its impact?,
  77. (2007). PET-Based Treatment Planning in Radiotherapy: A New Standard?,
  78. (2002). PET-CT alters management of patients with gynecologic cancers,
  79. (2004). PET/CT and breast cancer,
  80. (2005). PET/CT Detection of Unexpected Gastrointestinal Foci of 18F-FDG Uptake: Incidence, Localization Patterns, and Clinical Significance,
  81. PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI,
  82. (2003). PET/CT imaging in recurrent head and neck cancer,
  83. (2006). PET/CT imaging in response evaluation of patients with small cell lung cancer,
  84. (2004). PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies,
  85. (2004). PET/CT scanner instrumentation, challenges and solutions,
  86. (2003). PET/CT scanners: A hardware approach to image fusion,
  87. (2004). PET/CT today and tomorrow,
  88. PET/CT using 18F-FDG in Suspected Lung Cancer Recurrence: Diagnostic Value and Impact on Patient Management,
  89. (2005). PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients,
  90. (2003). PET/CT: a new imaging technology in nuclear medicine,
  91. (2006). Positron emission tomography,
  92. (2004). Positron emission tomography: a review of basic principles, scanner design and performance, and current systems,
  93. (2002). Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review,
  94. (2006). Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma,
  95. (2005). Positron emission tomography/computed tomography true fusion imaging in clinical head and neck oncology: Early experience,
  96. (2006). Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy,
  97. (2006). Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives,
  98. Prognostic Value of Positron Emission Tomography Using F-18-Fluorodeoxyglucose in Patients with Cervical Cancer Undergoing Radiotherapy,
  99. (1998). Proliferative myositis: a case of a pseudomalignant process,
  100. (2004). Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer,
  101. (2002). Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer,
  102. (2002). Prospects for quantitative computed tomography imaging in the presence of foreign metal bodies using statistical image reconstruction,
  103. (2003). Radiation Treatment Planning with An Integrated Positron Emission and Computer Tomography (PET/CT): A Feasibility Study,
  104. (2007). Radiotherapy Adapted to Spatial and Temporal Variability in Tumor Hypoxia,
  105. (2005). Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume,
  106. (2005). Review: Developments in nuclear cardiology: Transition from single photon emission computed tomography to positron emission tomography/computed tomography,
  107. (2006). Role of PET-CT in the optimization of thoracic radiotherapy,
  108. (2006). Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations,
  109. (2005). Staging and follow-up of gastrointestinal tumours with PET/CT,
  110. (2003). Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography,
  111. (2005). The additional value of PET/CT over PET in FDG imaging of oesophageal cancer,
  112. (2005). The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer,
  113. (2006). The contribution of PET/CT to improved patient management,
  114. (2005). The diabetic foot: initial experience with
  115. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynaecological malignancies,
  116. (2006). The impact of PET/CT in the management of recurrent ovarian cancer,
  117. (2007). The Impact of Positron Emission Tomography/Computed Tomography in Edge Delineation of Gross Tumor Volume for Head and Neck Cancers,
  118. (2006). The role of FDG-PET/CT in suspected recurrence of breast cancer,
  119. (2006). The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma,
  120. (1998). The SMART Scanner: a Combined PET/CT Tomograph for Clinical Oncology,
  121. (2005). The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate,
  122. Towards multidimensional radiotherapy (MD-CRT): Biological Imaging and Biological Conformity,
  123. (2005). Unknown Primary Tumours: Detection with Dual-Modality
  124. (2003). Value of [11C] Choline Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison with [18F] Fluorodeoxyglucose-Positron Emission Tomography,
  125. (2006). Variability of gross tumour volume delineation in head-and-neck cancer using CT and PET/CT,
  126. (2004). Why most PET of lung and head-and-neck cancer will be PET/CT,
  127. (2004). Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT,
  128. (2003). X-ray-based attenuation correction for positron emission tomography/computed tomography scanners,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.